Your browser doesn't support javascript.
loading
Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.).
Weiss, Jonathan; Peifer, Martin; Herling, Carmen D; Frenzel, Lukas P; Hallek, Michael.
Affiliation
  • Weiss J; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf jonathan.weiss@uk-koeln.de.
  • Peifer M; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne.
  • Herling CD; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
  • Frenzel LP; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf.
  • Hallek M; University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf.
Haematologica ; 104(11): e540, 2019 11.
Article in En | MEDLINE | ID: mdl-31666345
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell Limits: Humans Language: En Journal: Haematologica Year: 2019 Document type: Article Country of publication: Italy
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell Limits: Humans Language: En Journal: Haematologica Year: 2019 Document type: Article Country of publication: Italy